SCHEMBL918394

SCHEMBL918394

CCCc1c(O)cc(C=Cc2cc(F)cc(F)c2)cc1O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.51
PPARA Q07869 2/20 0.51
PTGS1 P23219 5/20 0.50
PTGS2 P35354 3/20 0.50
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NQO2 P16083 1/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
BACE1 P56817 1/20 0.38
ALOX5 P09917 1/20 0.36
TRPV1 Q8NER1 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
TUBB1 Q9H4B7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6469802 1.00 PPARG (0.51) PPARGPPARAPTGS1PTGS2NPC1
SCHEMBL6450483 0.87 PPARG (0.41) PPARGPPARAPTGS1PTGS2NPC1
SCHEMBL6450486 0.87 PPARG (0.41) PPARGPPARAPTGS1PTGS2NPC1
SCHEMBL6311612 0.87 PPARG (0.41) PPARGPPARAPTGS1PTGS2NPC1
SCHEMBL6469970 0.86 PPARG (0.53) PPARGPPARAPTGS1PTGS2NQO2
SCHEMBL919514 0.86 PPARG (0.53) PPARGPPARAPTGS1PTGS2NQO2
SCHEMBL6459991 0.85 PTGS1 (0.59) PTGS1PTGS2NQO2
SCHEMBL918488 0.85 PTGS1 (0.59) PTGS1PTGS2NQO2
SCHEMBL6469243 0.83 NPC1 (0.37) PPARGPPARAPTGS1PTGS2NPC1
SCHEMBL6469241 0.83 NPC1 (0.37) PPARGPPARAPTGS1PTGS2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059733-A1 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues WELICHEM BIOTECH, INC. 2005-03-17 US claimed
US-7868047-B2 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues WELICHEM BIOTECH INC. (CA) 2011-01-11 US disclosed
US-20100094041-A1 ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES WELICHEM BIOTECH INC. (CA) 2010-04-15 US disclosed
US-20080139666-A1 Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues WELICHEM BIOTECH INC. (CA) 2008-06-12 US disclosed
US-20050059733-A1 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues WELICHEM BIOTECH, INC. 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059733-A1 Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues NFKBIA, IKBKB, IKBKE PPARG 589/4885PPARA 683/4885PTGS1 275/4885
US-20080139666-A1 Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues LTK, MMP8, CHUK PPARG 1371/4885PPARA 1534/4885PTGS1 430/4885
US-20100094041-A1 ANTI-INFLAMMATORY AND PSORIASIS TREATMENT AND PROTEIN KINASE INHIBITION BY HYDROXY STILBENES AND NOVEL STILBENE DERIVATIVES AND ANALOGUES CHUK, MAP3K8, MAP3K1 PPARG 636/4885PPARA 782/4885PTGS1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.